Healthcare services company Curative Insurance Company and GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of Galleri, a multi-cancer early detection (MCED) screening test to eligible insurance plan members. 

The Galleri test will be available to all members, across all plan types, who are over the age of 50 and to all other members with risk factors for developing cancer.(1) The Galleri test is part of the list of benefit offerings available for $0 copay and $0 deductible* on Curative’s health insurance plan.

A simple blood draw used in addition to current single-cancer screenings, Galleri can identify DNA shed by cancer cells to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others, according to the company. Studies have shown a 75% sensitivity for screening cancers responsible for two-thirds of cancer deaths, rising as high as 80% for the most serious cancers. Galleri can indicate the origin of the cancer with 88% accuracy, giving doctors a roadmap for where to explore further.(2, 3, 4)

“We are excited to be working with GRAIL and proud to offer Curative health plan members the groundbreaking Galleri test that is truly key in helping detect cancer early on for our members,” says Fred Turner, CEO and co-founder of Curative. “Preventive care is at the core of our health insurance plan, and the Galleri test may allow qualified members to screen for potential cancer early, before any symptoms appear when it may be more easily treated and potentially curable. This is not just about early detection; it’s also about empowering our members with the tools to be proactive with their health. Curative’s partnership with GRAIL is a testament to our commitment to preventive care and the well-being of our members.”

Further reading: GRAIL Study To Evaluate Multi-Cancer Early Detection Test for Medicare Population

“Single-cancer screenings play an important role in detecting five specific cancers today. However, nearly 70% of deaths are caused by cancers that don’t have recommended screenings,” says Bob Ragusa, CEO at GRAIL. “By providing the Galleri test to eligible health insurance members, Curative is helping to screen for the deadliest cancers that often come with no warning today, demonstrating their commitment to preventative and proactive care.”

Curative members eligible for Galleri may request the test through an independent telemedicine provider at Curative’s health insurance plan includes an annual preventive care visit called the Baseline Visit, where members get the opportunity to speak with a Curative clinician about their overall health. In addition, plan members are assigned a personal Healthcare Navigator, who walks members through health plan benefits and onboard members, setting up a roadmap for whole health and showing the member their 24/7 telemedicine plan feature.

Curative’s unique $0 copay, $0 deductible plan* offers comprehensive coverage, encompassing wellness, preventive care, behavioral health services, primary and specialty care, office and hospital visits, prescription drugs, and all accessible through a high-quality PPO network at competitive monthly premiums, according to the company. The Curative plan is currently available to employers headquartered in Texas and Florida with 50 or more eligible employees nationwide, with broad national network coverage and access to almost 1 million providers nationwide.

*Every Curative member qualifies for the $0 deductible, $0 copay for in-network care and preferred prescriptions by completing a Baseline Visit within 120 days of the plan effective date. Curative Insurance Company PPO. GA240129-1.


  2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. Doi: 10.1016/j.annonc.2021.05.806.
  3. American Cancer Society. Cancer Facts & Figures. 2021. Available at:
  4. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2.